<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ARSci</journal-id><journal-title-group><journal-title>Advances in Reproductive Sciences</journal-title></journal-title-group><issn pub-type="epub">2330-0744</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/arsci.2024.121005</article-id><article-id pub-id-type="publisher-id">ARSci-131381</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Pregnancy and Obstetrical Outcomes Following Treatment for Cervical Intra-Epithelial Neoplasia (CIN) in Two Hospitals of a Low-Resource Country
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bruno</surname><given-names>Kenfack</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Clovis-Achille</surname><given-names>Tanekeu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Atem</surname><given-names>Bethel Ajong</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zabdielle</surname><given-names>Blonde Goufack Kenfack</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Patrick</surname><given-names>Petignat</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pierre</surname><given-names>Marie Tebeu</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Kekem MD, District Hospital, West Region, Cameroon</addr-line></aff><aff id="aff4"><addr-line>Department of Epidemiology and Public Health, Faculty of Medicine and Pharmaceutical Science, University of Dschang, Dschang, Cameron</addr-line></aff><aff id="aff6"><addr-line>Faculty of Medicine and Biomedical Science, University of Yaounde I, Yaounde, Cameroon</addr-line></aff><aff id="aff2"><addr-line>Institur Supérieur des Sciences de la Santé, Université des Montagnes, Bangangté, Cameroon</addr-line></aff><aff id="aff5"><addr-line>Geneva University Hospitals, Genevas, Switzerland</addr-line></aff><aff id="aff1"><addr-line>Department of Gynecology and Obstetrics, Faculty of Medicine and Pharmaceutical Science, University of Dschang, Dschang, Camer-on</addr-line></aff><pub-date pub-type="epub"><day>27</day><month>12</month><year>2023</year></pub-date><volume>12</volume><issue>01</issue><fpage>51</fpage><lpage>59</lpage><history><date date-type="received"><day>17,</day>	<month>December</month>	<year>2023</year></date><date date-type="rev-recd"><day>24,</day>	<month>February</month>	<year>2024</year>	</date><date date-type="accepted"><day>27,</day>	<month>February</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Objective:
  <b> </b>
  In Cameroon, more than 80% of women suffering from cervical intraepithelial neoplasia (CIN) are within the reproductive age. This study intended to analyze the pregnancy outcomes following cervical treatment in Cameroon.
   
  <b>Methods:</b>
  <b> </b>
  This was a cohort study with two years retrospective data collection involving 82 women who underwent cervical treatment for CIN in two Cameroonian hospitals from January 2015 to December 2017. Data were collected from CIN treatment to end of pregnancy where applicable. Data analysis was done using Epi Info software version 3.5.4.
   
  <b>Results:</b>
  <b> </b>
  We collected data from 82 patients aged 27 to 48 years, with a mean age of 36.5 (SD: 5.3) years. During the study period, 33 out of 82 participants became pregnant 40.2 [29.56
   
  -
   
  51.66]%. The factor associated with pregnancy occurrence after treatment was age less than 35 years (Odds ratio = 4.37 
  [1.7
   
  -
   
  11.2
  ]. From the 33 pregnancies recorded, 17 (51.5%) ended in a delivery, amongst which 15 (88.2%) were vaginal.
   
  <b>Conclusion:</b>
  <b> </b>
  Pregnancy 
  frequency
   over two years following cervical treatment for CIN was relatively good, and younger women (age &lt;
   
  35 years) were significantly more like to have conceived compared to their older counterparts. Post-treatment delivery outcomes seem to be similar to those in the general population.
 
</p></abstract><kwd-group><kwd>Cervical Intraepithelial Neoplasia</kwd><kwd> Cervical Treatment</kwd><kwd> Pregnancy Outcome</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Cervical intraepithelial neoplasia (CIN) is defined as precancerous lesions caused by HPV (human papilloma virus), comprising three stages: CIN 1, CIN 2, and CIN 3 [<xref ref-type="bibr" rid="scirp.131381-ref1">1</xref>] . The World Health Organization (WHO) recommends that high-grade CIN be treated by fertility-preserving methods which include ablative treatments (cryotherapy and thermalablation) or excisional methods (large loop excision of the transformation zone (LLETZ), large electrosurgical excision procedure (LEEP) and cold knife conisation) [<xref ref-type="bibr" rid="scirp.131381-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.131381-ref3">3</xref>] . Thermalablation equipment is simple, easily portable (less than 2 kg), and is among the methods of choice used for the treatment as recommended by WHO [<xref ref-type="bibr" rid="scirp.131381-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.131381-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.131381-ref5">5</xref>] . In Cameroon, the treatment methods used are cryotherapy, thermalablation, and conisation.</p><p>Studies in America and Europe on pregnancy after CIN cervical conisation reported obstetrical complications including premature rupture of membranes, premature delivery, low birth weight, associated with increased perinatal mortality [<xref ref-type="bibr" rid="scirp.131381-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.131381-ref7">7</xref>] . Evidence on the impact of thermal ablation and cryotherapy on fertility and premature delivery is still uncertain.</p><p>In 2013, a Cameroonian study reported a cervical dysplasia percentage of 3.9%, and the age group of 34 to 49 years to be the most affected [<xref ref-type="bibr" rid="scirp.131381-ref8">8</xref>] . In 2017, another study in the same country registered 14% of high-grade intraepithelial lesions in women aged 30 to 49 years, a majority of which still had future pregnancy desires [<xref ref-type="bibr" rid="scirp.131381-ref4">4</xref>] . Little is known about pregnancy rate and their outcome after fertility-preserving treatment methods for CIN in Cameroon.</p><p>The objective of the study was to assess the pregnancy rate and obstetrical outcome after locally cervical treatment of CIN in Cameroon.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Study Design, Setting and Period</title><p>This was a cohort retrospective study involving patient’s record review with associated patient interview conducted in the Departments of Gynaecology and Obstetrics of two Cameroonian hospitals; the Yaound&#233; University Teaching Hospital (YUTH), and the Dschang District Hospital (DDH). The YUTH is a central level health facility located in urban Cameroon (Yaound&#233;, the political capital of Cameroon) while the DDH is a first level referral hospital in the health pyramid, located in a semi-rural area. Each of these hospitals offers preventive and curative care for precancerous lesions of the cervix to more than 1 000 women per year. The study period spanne from January 2015 to December 2017 and the data was collected in March 2018.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>We included all women aged 25 - 49 who underwent locally cervical treatment for CIN in the two settings and who expressed a desire for pregnancy in the future. We excluded women who did not come for the interview, those not exposed to pregnancy (not sexually active since treatment or on contraception or who declared at interview that they avoided pregnancy during the study period), and those with incomplete medical records. Also, all women with a post-therapeutic experience of less than two years were not included. Of the 252 women treated for CIN, 126 expressed a desire for pregnancy, out of which 82 were eligible.</p><p>Our sample size was exhaustive, enrolling all women who met our inclusion criteria.</p></sec><sec id="s2_3"><title>2.3. Procedure of Implementation and Data Collection</title><p>Administrative authorizations were obtained from the directors of both settings. Data collection was done by a review of patients’ records and face to face through an interview by a medical student trained on the consenting and data collection procedure. The data collection tool was a questionnaire, which was composed of questions on the women’s socio-demographic characteristics, past fertility/obstetric history, cervical treatment administered, and questions to evaluate their post-therapeutic exposure to sexual intercourse as well as their pregnancy status and outcomes following treatment. Medical records of women treated by local cervical methods for precancerous lesions were reviewed to collect preliminary existing information on the predesigned data collection sheet. Women were called by phone or approached during their normal scheduled consultations for this procedure. After a complete explanation of the information sheet of the study to the woman consent to participate was obtained, concretized by the signing of the informed consent form. The questionnaire was administered face-to-face and one-to-one in closed settings.</p></sec><sec id="s2_4"><title>2.4. Data Analysis</title><p>The statistical software Epi-Info version 3.5.4 was used for data analysis. Proportions with their 95% confidence intervals were calculated for categorical variables. Means or medians (where applicable) were calculated for continuous variables. The homogeneity of the distribution of variables around pregnancy occurrence and non-pregnancy occurrence groups was accessed using Pearson Chi square test or Fisher exact test. Associations were quantified using Crude Odd Ratio (OR) and their 95% confidence intervals, and when appropriate, adjusted Odd Ratio Ratio (OR<sup>a</sup>) by multivariate analysis. The level of significance was set at p &lt; 0.05.</p></sec><sec id="s2_5"><title>2.5. Ethical Considerations</title><p>Ethical approval was obtained from the institutional ethical review board of the “Universit&#233; des Montagnes” (N˚2018/066/UdM/PR/CIE). Participants were included after a written informed consent, the data collection tool was anonymous and information collected kept confidential.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Pregnancy Occurrence</title><p>During the study period, 252 women were treated for CIN, and among them 126 expressed pregnancy desires. Pregnancy occurred in 33 of 82 women (40.2%). Participant’s ages ranged from 27 to 48 years, with a mean age of 36.5 &#177; 5.3 years. <xref ref-type="table" rid="table1">Table 1</xref> presents the baseline clinical characteristics of the participants stratified by pregnancy occurrence.</p><p>The pregnancy rate among women aged less than 35 years was 60.0% as opposed to the 25.5% registered in older women, the difference being statistically significant (P = 0.001). Pregnancy rate was significantly higher in participants with past history of contraception (64.3%) than in those who have never used if (35.3%). Past history of sexually transmitted infection and of infertility were not associated with higher rate of post-therapeutic pregnancy. Factors associated with pregnancy occurrence after treatment, are presented in <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>Age below 35 years crude odd ratio (OR<sup>a</sup>) = 4.37 [1.7 - 11.22] and history of</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline clinical characteristics of the participants stratified by pregnancy occurrence</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="3"  >Characteristics</th><th align="center" valign="middle"  rowspan="3"  >Total (N = 82)</th><th align="center" valign="middle"  colspan="4"  >Pregnancy after treatment</th><th align="center" valign="middle"  rowspan="3"  >p-value</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Yes</td><td align="center" valign="middle"  colspan="2"  >No</td></tr><tr><td align="center" valign="middle" >N = 33</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >N = 49</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Mean age (SD<sup>a</sup>)</td><td align="center" valign="middle" >36.5 (5.3)</td><td align="center" valign="middle" >34.5 (4.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >37.8 (5.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.0067</td></tr><tr><td align="center" valign="middle"  colspan="7"  >Age group</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;35</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >60.00</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >40.00</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >≥35</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >25.5</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >74.5</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="7"  >Past history of contraception</td><td align="center" valign="middle" >0.043</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >64.3</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >35.7</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >35.3</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >64.7</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="7"  >Past history of STI</td><td align="center" valign="middle" >0.379</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >31.6</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >68.4</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >42.9</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >57.1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="7"  >Past history of infertility</td><td align="center" valign="middle" >0.143</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >14.3</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >85.7</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >42.7</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >57.3</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p><sup>a</sup>Standard deviation.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Factors associated with pregnancy occurrence following cervical treatment for CIN (bivariate and multivariate analysis)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="3"   rowspan="3"  >Characteristics</th><th align="center" valign="middle"  colspan="5"  >Pregnancy after treatment</th><th align="center" valign="middle"  rowspan="3"  >OR<sup>a</sup> (IC95%)</th><th align="center" valign="middle"  rowspan="3"  >p<sup> </sup></th><th align="center" valign="middle"  rowspan="3"  ><sup>b</sup>OR</th><th align="center" valign="middle"  rowspan="3"  >p</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >Total (n = 82)</td><td align="center" valign="middle"  colspan="2"  >Yes (n = 33)</td><td align="center" valign="middle"  colspan="2"  >No (n = 49)</td></tr><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Age less than 35</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >60.0</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >40.0</td><td align="center" valign="middle" >4.37 (1.7 - 11.2)</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >3. 66 (1.3 - 10.32)</td><td align="center" valign="middle" >0.014</td></tr><tr><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >25.5</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >74.5</td><td align="center" valign="middle" >1 <sup>c </sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1<sup>c </sup></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Contraception</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >64.3</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >35.7</td><td align="center" valign="middle" >3.3 (1.03 - 10.9)</td><td align="center" valign="middle" >0.043</td><td align="center" valign="middle" >2. 67 (0.65 - 11.26)</td><td align="center" valign="middle" >0.179</td></tr><tr><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >35.3</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >64.7</td><td align="center" valign="middle" >1<sup>c </sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1<sup>c </sup></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Past history STI</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >42.9</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >57.1</td><td align="center" valign="middle" >1.62 (0.54 - 4.82)</td><td align="center" valign="middle" >0.379</td><td align="center" valign="middle" >4.73 (0.44 - 49.94)</td><td align="center" valign="middle" >0.196</td></tr><tr><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >31.6</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >68.4</td><td align="center" valign="middle" >1<sup>c </sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1<sup>c </sup></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="4"  >History of infertility</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >No</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >42.7</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >57.3</td><td align="center" valign="middle" >4.46 (0.51 - 38.94)</td><td align="center" valign="middle" >0.143</td><td align="center" valign="middle" >1.35 (0.39 - 4.71)</td><td align="center" valign="middle" >0.630</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >Yes</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >14.3</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >85.7</td><td align="center" valign="middle" >1<sup>c </sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1<sup>c </sup></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>OR<sup>a</sup> crude Odds Ratio; OR<sup>b</sup> adjusted Odds Ratio; <sup>c</sup>Reference; P: P-value.</p><p>contraceptive use: OR<sup>a</sup> = 3.3 [1.03 - 10.9] were associated with increased likelihood of pregnancy occurrence. During multivariate analysis, only the age below 35 years was associated with the occurrence of pregnancy following cervical treatment of CIN adjusted odd ratio (OR<sup>b</sup>) = 3.66 [1.3 - 10.32].</p></sec><sec id="s3_2"><title>3.2. Pregnancy Outcomes</title><p>The flow chart (<xref ref-type="fig" rid="fig1">Figure 1</xref>) presents pregnancy outcomes within the study population.</p><p>Among the 82 treated women who expressed fertility desires, thirty-three pregnancies were recorded 40.2%, out of which 13 (51.5%) ended in childbirth and 6 (18.2%) were still in progress at the end of the study. There were 5/33 (15.2%) spontaneous abortions, 2 in the first trimester, and 3 in the second trimester. There were also 5/33 (15.2%) induced abortions, initiated by women who estimated the occurrence of their pregnancies to be too early.</p><p>Finally, 17 women gave birth among which, 15 normal term vaginal deliveries (88.2%), one term cesarean section (5.9%), and one preterm vaginal delivery (5.9%). A single second-trimester abortion was recorded among participants from each treatment entity, (i.e.: conization, cryotherapy, and thermal ablation).</p><p>Pregnancy occurrence over time from treatment is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>Pregnancies were mostly recorded between the 10<sup>th</sup> and 12<sup>th</sup>-month post-therapy.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>The study aimed to determine the pregnancy occurrence and outcome in women after cervical treatment for CIN. This pilot study is the first step to provide an answer to one of the main worries about cervical cancer prevention, which is childbearing after treatment. As an addition to other studies, all our participants had biopsy-proven CIN.</p><p>We found a post-therapeutic pregnancy rate of 40.2%, similar to the 43% reported by Kyrgiou in a meta-analysis of four studies including 38,050 participants [<xref ref-type="bibr" rid="scirp.131381-ref6">6</xref>] . This percentage is higher than the 20% rate reported in France by Omnes et al. on 20 patients all treated by conisation in 2003, and the 12.78% obtained by Chafika et al. in 2004 on a larger size of 460 patients all treated by conisation in France [<xref ref-type="bibr" rid="scirp.131381-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.131381-ref10">10</xref>] . Our pregnancy rate is also higher than the 14% found by Naleway et al. in a meta-analysis including 4127 patients treated with different fertility-preserving methods (Cryotherapy Large Loop Excision of Transformation Zone and Cold knife biopsy), apart from thermal ablation [<xref ref-type="bibr" rid="scirp.131381-ref7">7</xref>] . This can be explained by the fact that their most representative age group was 20 to 29 years, ages at which the majority of women in the developed countries where these studies were carried out do not yet express the desire for maternity [<xref ref-type="bibr" rid="scirp.131381-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.131381-ref9">9</xref>] . Another possible explanation is that more than half of their patients were on contraceptives during the study period [<xref ref-type="bibr" rid="scirp.131381-ref9">9</xref>] . Our reported post-therapeutic pregnancy rate is however low compared to the normal cumulative conception rates described in the general population. Cumulative spontaneous conception rates stand at 75% after 6 months, 90% after a year, and 95% over two years [<xref ref-type="bibr" rid="scirp.131381-ref11">11</xref>] . This rate is described to drop significantly in the 30 s and 40 s (typical of our study population given that the mean age of our participants was 36.5 &#177; 5.32) to about 60% over a year and 85% in two years among women aged 35 - 39 years [<xref ref-type="bibr" rid="scirp.131381-ref11">11</xref>] .</p><p>History of contraceptive use before treatment also appears to be a factor increasing by 3 folds the chances of having a pregnancy, (crude OR 3.3 [1.03 - 10.9]), p-value: 0.04. This can be explained by the fact that only potentially fertile women generally seek contraception. After screening and treatment, most of them stop using contraception to fulfill their childbearing desire before any possible pathology that may compromise their fertility.</p><p>Age below 35 years appears to be significantly associated with higher post-therapeutic pregnancy rate (crude OR: 4.37 [1.7 - 11.2], p = 0.001). This is the only significant factor increasing the chances of having a pregnancy by more than four-folds. In rural areas of low-resource countries, a majority of women have already attained their desired number of children by the age of 35. Those with pregnancy desires beyond that age may be hypo or infertile. According to the Demographic and Health Survey 5 of Cameroon, the fertility rate by age group falls from 196/1000 to 139/1000 between the 30 - 34 and 35 - 39 years age groups respectively [<xref ref-type="bibr" rid="scirp.131381-ref12">12</xref>] . However, given that our sample size was small, large scale studies are still needed to be able to fully identify factors associated with pregnancy following cervical treatment of CIN.</p><p>As concerns pregnancy outcomes, of the 33 pregnancies, 17 (51.5%) ended in childbirth. Among the 17 deliveries, we noted 15 (88.2%) term vaginal deliveries. Our observed 5.9% cesarean section rate falls within the range of 5% to 15% recommended by the WHO [<xref ref-type="bibr" rid="scirp.131381-ref13">13</xref>] .</p><p>We recorded 5.9% (1/17) premature delivery, a percentage lower than 7 to 14% reported by Kirgiou et al. in 2006 in a systematic review, the percentage being higher in women treated with conization [<xref ref-type="bibr" rid="scirp.131381-ref14">14</xref>] . Our recorded percentage ranges within the WHO estimated 5% - 15% in the general population [<xref ref-type="bibr" rid="scirp.131381-ref15">15</xref>] . However, our results are questionable due to the small sample size. Nonetheless, this observation allows us to support that fertility-preserving treatments may not be a risk factor of premature deliveries while waiting for the results of studies with larger sample sizes.</p><p>We found five cases (15.2%) of participant-initiated induced abortions, all in women who conceived within the first nine months following treatment because they considered their pregnancy occurred too early. The WHO recommends a 12 months follow-up after cervical fertility-preserving treatment of CIN [<xref ref-type="bibr" rid="scirp.131381-ref2">2</xref>] . Consequently, the early conception and subsequent participant-initiated induced abortions observed in our study stress the need for a one-year contraception prescription following local cervical treatment of CIN.</p><p>A spontaneous abortion rate of 15.2% was observed, with a predominance of late abortions (3/5). A Norwegian study reported that the miscarriage rate increases with women’s age, from 10% at the age of 30 to 30% at the age of 40 [<xref ref-type="bibr" rid="scirp.131381-ref16">16</xref>] . With the 15.2% pregnancy loss found in our study, we can conclude that fertility-preserving cervical treatment for CIN may not increase the risk of pregnancy loss.</p><p>The study gives some pilot information on pregnancy outcome after cervical treatment of CIN. The limits are mainly those related to the retrospective data collection, the small sample size, and the lack of control.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The two years cumulative pregnancy rate following cervical fertility-preserving treatment of CIN is 40.2%, with age below 35 years associated with a higher pregnancy occurrence. Post-treatment delivery outcomes seem to be similar to those in the general population. These results need to be confirmed by studies with larger sample sizes. There is a high rate of women-initiated induced abortion for those that conceived within the first months after treatment, stressing the need of inserting a contraceptive package in cervical cancer prevention activities.</p></sec><sec id="s6"><title>Acknowledgements</title><p>Our sincere gratitude’s goes to:</p><p>&#183; Nguefack-Tsague Georges for his contribution to article review.</p><p>&#183; Mawamba Yvette for patient’s screening and treatment in YUTH.</p><p>&#183; Ossondo Nlom Marl&#232;ne for protocol and thesis review.</p><p>&#183; Nurses of the cervical cancer prevention units of YUTH and DDH.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Kenfack, B., Tanekeu, C.-A., Ajong, A.B., Kenfack, Z.B.G., Petignat, P. and Tebeu, P.M. (2024) Pregnancy and Obstetrical Outcomes Following Treatment for Cervical Intra-Epithelial Neoplasia (CIN) in Two Hospitals of a Low-Resource Country. Advances in Reproductive Sciences, 12, 51-59. https://doi.org/10.4236/arsci.2024.121005</p></sec></body><back><ref-list><title>References</title><ref id="scirp.131381-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2023) Cervical Cancer.  
https://www.who.int/news-room/fact-sheets/detail/cervical-cancer</mixed-citation></ref><ref id="scirp.131381-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2014) Comprehensive Cervical Cancer Control. A Guide to Essential Practice—Second Edition.  
https://www.who.int/publications-detail-redirect/9789241548953</mixed-citation></ref><ref id="scirp.131381-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Viviano, M., Kenfack, B., Catarino, R., et al. (2017) Feasibility of Thermocoagulation in a Screen-and-Treat Approach for the Treatment of Cervical Precancerous Lesions in Sub-Saharan Africa. BMC Women’s Health, 17, Article No. 2. 
https://doi.org/10.1186/s12905-016-0355-x</mixed-citation></ref><ref id="scirp.131381-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Tran, P.L., Kenfack, B., Tincho Foguem, E., et al. (2017) Efficacy of Thermoablation in Treating Cervical Precancerous Lesions in a Low-Resource Setting. International Journal of Women’s Health, 9, 879-886. https://doi.org/10.2147/IJWH.S142911</mixed-citation></ref><ref id="scirp.131381-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2019) WHO Guidelines for the Use of Thermal Ablation for Cervical Pre-Cancer Lesions.  
https://www.who.int/publications-detail-redirect/9789241550598</mixed-citation></ref><ref id="scirp.131381-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kyrgiou, M., Mitra, A., Arbyn, M., et al. (2015) Fertility and Early Pregnancy Outcomes after Conservative Treatment for Cervical Intraepithelial Neoplasia. Cochrane Database of Systematic Reviews, Article No. CD008478.  
https://doi.org/10.1002/14651858.CD008478.pub2</mixed-citation></ref><ref id="scirp.131381-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Naleway, A.L., Weinmann, S., Krishnarajah, G., et al. (2015) Pregnancy after Treatment for Cervical Cancer Precursor Lesions in a Retrospective Matched Cohort. PLOS ONE, 10, e0117525. https://doi.org/10.1371/journal.pone.0117525</mixed-citation></ref><ref id="scirp.131381-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Marie, T.P., Sando, Z., et al. (2013) Prevalence and Geographical Distribution of Precancerous Lesions of the Uterine Cervix in Cameroon. Journal of Cytology &amp; Histology, 4, Article ID: 1000183. https://doi.org/10.4172/2157-7099.1000183</mixed-citation></ref><ref id="scirp.131381-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mazouni, C., Porcu, G., Haddad, O., et al. (2005) Conservative Treatment of Cervical Intraepithelial Neoplasia Using a Cold-Knife Section Technique. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology, 121, 86-93.  
https://doi.org/10.1016/j.ejogrb.2004.11.018</mixed-citation></ref><ref id="scirp.131381-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Omnes, S., Morice, P., Camatte, S., et al. (2003) Modalities and Limits of Conservative Treatment of Adenocarcinoma in situ of the Uterine Cervix: Analysis of Nine Cases and Review of the Literature. Gynécologie Obstétrique &amp; Fertilité, 31, 912-919. https://doi.org/10.1016/j.gyobfe.2003.08.016</mixed-citation></ref><ref id="scirp.131381-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Taylor, A. (2003) Extent of the Problem. BMJ, 327, 434-436. 
https://doi.org/10.1136/bmj.327.7412.434</mixed-citation></ref><ref id="scirp.131381-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Institut National de la Statistique (2015) Enquête par grappes à indicateurs multiples (MICS5), 2014, Rapport Final. Yaoundé, Cameroun, Institut National de la Statistique. 
https://mics-surveys-prod.s3.amazonaws.com/MICS5/West%20and%20Central%20Africa/Cameroon/2014/Final/Cameroon%202014%20MICS_French.pdf</mixed-citation></ref><ref id="scirp.131381-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2015) WHO Statement on Caesarean Section Rates.  
https://www.who.int/publications-detail-redirect/WHO-RHR-15.02</mixed-citation></ref><ref id="scirp.131381-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kyrgiou, M., Koliopoulos, G., Martin-Hirsch, P., et al. (2006) Obstetric Outcomes after Conservative Treatment for Intraepithelial or Early Invasive Cervical Lesions: Systematic Review and Meta-Analysis. Lancet, 367, 489-498. 
https://doi.org/10.1016/S0140-6736(06)68181-6</mixed-citation></ref><ref id="scirp.131381-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2023) Preterm Birth.  
https://www.who.int/news-room/fact-sheets/detail/preterm-birth</mixed-citation></ref><ref id="scirp.131381-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Magnus, M.C., Wilcox, A.J., Morken, N.-H., et al. (2019) Role of Maternal Age and Pregnancy History in Risk of Miscarriage: Prospective Register Based Study. BMJ, 364, l869. https://doi.org/10.1136/bmj.l869</mixed-citation></ref></ref-list></back></article>